Skip to content

ROPIVACAINE AND BUPIVACAINE AS LOCAL ANAESTHETIC IN OPEN INGUINAL HERNIA SURGERY

COMPARISON OF ROPIVACAINE VS BUPIVACAINE AS LOCAL ANAESTHETIC AGENT IN OPEN INGUINAL HERNIA SURGERY- A RANDOMISED CONTROL TRIAL - ROBU trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045900
Enrollment
56
Registered
2022-09-26
Start date
Unknown
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K409- Unilateral inguinal hernia, without obstruction or gangrene

Interventions

Intervention1: Ropivacaine arm: 0.5% of the anesthetic agent will be infiltered along the incision line and the cord for local anesthesia. 200mg maximum dose of Ropivacaine will be used. Control Inte

Sponsors

AIIMS Bhubaneswar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All those undergoing inguinal hernia surgery under local anesthesia above 18 years

Exclusion criteria

Exclusion criteria: a)Prior involvement in another study. b)Known allergy to Bupivacaine/ Ropivacaine or hypersensitivity reaction detected after the test dose c)Patients who are suffering from Cardiac and respiratory disorders. d)Patients not able to understand the nature of the study g)Patients with complicated inguinal hernia

Design outcomes

Primary

MeasureTime frame
pain experienced measured by VASTimepoint: start of surgery 6 hours 12 hours 18 hours 24 hours

Secondary

MeasureTime frame
To compare the need for rescue analgesic in either arm till 24hrs or discharge. To assess overall patient satisfaction in either arm at 24hrs or discharge. To compare the postoperative complications of either arm due to anaesthetic agent. To assess the duration of hospital stay in either arm. Timepoint: At the end of the surgery and 6, 12, 18 & 24 hours following it.

Countries

India

Contacts

Public ContactShriganesh Shastri

AIIMS BHUBANESWAR

mks132@gmail.com09438884252

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026